QNCX - NASDAQ
Quince Therapeutics, Inc.
$1.36
+0.0000%Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
At a Glance
Live SnapshotQuince Therapeutics, Inc. Fair Value Envelope
Owner Earnings Valuation Tool
Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation
Historical Financial Data
Base year metrics used for projections
Projection Settings
Forecast period and terminal assumptions
DCF Valuation Summary
Calculation flow from present value to intrinsic value per share
Owner Earnings Projections
Operating Cash Flow - Maintenance CapEx = Owner Earnings
| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Year 6 | Year 7 | Year 8 | Year 9 | Year 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$16.0M | -$8.0M | -$4.0M | -$2.0M | -$997.0K | -$498.5K | -$249.3K | -$124.6K | -$62.3K | -$31.2K |
| Maintenance CapEx | -$25.7K | -$12.9K | -$6.4K | -$3.2K | -$1.6K | -$803 | -$402 | -$201 | -$100 | -$50 |
| Owner Earnings | -$16.0M | -$8.0M | -$4.0M | -$2.0M | -$998.6K | -$499.3K | -$249.7K | -$124.8K | -$62.4K | -$31.2K |
| Discount Factor | 0.926 | 0.857 | 0.794 | 0.735 | 0.681 | 0.630 | 0.583 | 0.540 | 0.500 | 0.463 |
| Present Value | -$14.8M | -$6.8M | -$3.2M | -$1.5M | -$679.6K | -$314.6K | -$145.7K | -$67.4K | -$31.2K | -$14.5K |
Related Guides
Continue your QNCX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.